Prior to the beginning of treatment, 114 patients with B-cell lymphoma treated with rituximab and chemotherapy had CD20 expression assessed by quantitative flow cytometric measurements. Our data show that patients who achieved complete response after rituximab therapy had a significantly higher expression of the CD20 antigen (p=0.018) than those whose disease only stabilized after rituximab therapy. Patients with a CD20 expression level above the cut-off value treated with rituximab had a significantly longer overall survival than patients with a CD20 expression level below the cut-off value.
COBISS.SI-ID: 1085563
When antioxidants were used during gene electrotransfer, the transfection efficiency of C2C12 myoblasts was statistically significantly increased 1.6-fold with antioxidant tempol. Also in vivo, the transfection efficiency of M. tibialis cranialis in mice was statistically significantly increased 1.4-fold by tempol. The study indicates that ROS are generated on cells during EP and can be scavenged by antioxidants.
COBISS.SI-ID: 2399567
The primary endpoint was pathological complete response (pCR) of neoadjuvant therapy in 61 patients (median age 60 years [range 31-80], 64% male) with stage II/III rectal cancer. They were treated by bevacizumab, neoadjuvant chemoradiotherapy and surgery. Radical resection was achieved in 57 patients (95%), and 42 patients (70%) underwent sphincter-preserving surgery. The observed adverse events of neoadjuvant treatment are comparable with those previously reported, but the pCR rate (=13.3%) was lower.
COBISS.SI-ID: 1148027